The genetic relationships are very close there. That's a lot of fun.

And then in addition, transgenic pigs, knockout pigs, from the National Institute of Animal Science in South Korea, are pigs that they are going to use, in fact, to try to create all kinds of drugs and other industrial types of chemicals that they want the blood and the milk of these animals to produce for them, instead of producing them in an industrial way.

Effort then becomes more important than having the right genes.

They were doing an experiment to do with genetics and the forelimbs and the hind limbs of animals.

They look at their entire genomes, and they try to find hot spots of activity that are linked causally to genes.

Many of the HARs are associated with genes known to play a role in neurodevelopment.

Depending on who you ask, only 5 to 8 of Alzheimer's is linked to a single gene to begin with.

So again, it's not just genes, it's multiple details our habits, our environmental exposure.

There are exciting new forms of gene therapy that overcome the problem of placing the genetic material in the right place on the chromosome.

There's actually a for the first time now, something going to human trials, that actually cures pulmonary hypertension a fatal disease using gene therapy.

Manufacturers claim that gene patents, which now cover 25 40 of the human genome, are vital to recouping their investments.

In complex systems terms, you could think of the genes as simple components that interact with other genes in a decentralized way.

A key area of research in the use of RNAi for clinical applications is the development of a safe delivery method, which to date has involved mainly viral vector systems similar to those suggested for gene therapy.

There are clear parallels between that situation and the way in which the common law has offered little redress to patients who have tried to claim property rights in tissue taken from them, or to activists seeking to limit the powers of Big Biotech over human genetic patents.